The webinar will feature a presentation by Key Opinion Leader (KOL) Richard S.E. Keefe, Ph.D. (Duke University), who will discuss the current treatment landscape and unmet medical need in treating patients with Cognitive Impairment Associated with Schizophrenia (CIAS). This condition may include deficits in attention, working memory, and executive function, which have a negative impact on patients’ quality of life and ability to function.

Matt Pando, Ph.D. (Co- Founder, President, and CEO of Recognify Life Sciences, Inc.) will discuss Atai Life Sciences’ Phase 2 program RL – 007, an investigational agent for the treatment of CIAS.

A question and answer session will follow.